CHPA responds to Food and Drug Administration’s APAP recommendation
WASHINGTON — The Consumer Healthcare Products Association on Thursday responded to the Food and Drug Administration’s recommendation to discontinue prescribing and dispensing prescription combination medicines that contain more than 325 mg of acetaminophen per dosage unit, suggesting it would not impact use of over-the-counter formulations containing acetaminophen.
“By limiting prescription products to no more than 325 mg acetaminophen, the FDA is addressing the biggest cause of unintentional acetaminophen overdose," the association stated. "More than half (63%) of reported overdose cases involve the use of prescription opioid-acetaminophen combination medicines, such as Vicodin and Percocet. Lowering the amount in prescription products will help reduce the risk of consumers accidentally exceeding the maximum daily dose of 4,000 mg."
The industry has taken several proactive steps to educate consumers about acetaminophen safe-use and increase the visibility of acetaminophen on OTC product labels to help consumers better understand how to avoid accidental overdose. This has included enhanced labeling on both the front package panel and the Drug Facts label to call out the word “acetaminophen” on all OTC medicines that contain the ingredient. It is now prominently listed on the principal display panel (front of package) and bolded or highlighted in the ingredients section of the Drug Facts label.
These initiatives are in tandem with FDA’s and others’ efforts on the prescription side to drive and improve acetaminophen safe use.
In addition, the CHPA Educational Foundation co-founded and actively participates on the Acetaminophen Awareness Coalition and its Know Your Dose campaign, which educates consumers to read and follow the medicine label, know if acetaminophen is an ingredient in your medicines, and never take two medicines with acetaminophen at the same time. Advisors to those initiatives include the FDA’s Safe Use Initiative and the Centers for Disease Control and Prevention.
CRN study defines dietary supplement users
WASHINGTON — The Council for Responsible Nutrition on Thursday created an infographic that depicts the dietary supplement consumer based on the association’s annual survey.
CRN’s mission behind this infographic was to provide an easily accessible – and easy to understand – resource with key data from the 2013 CRN Consumer Survey on Dietary Supplements, CRN stated.
Infographic from Council for Responsible Nutrition.
See www.crnusa.org/consumersurvey for more.
NCPA places support behind Diabetic Testing Supply Access Act
ALEXANDRIA, Va. — The National Community Pharmacists Association on Thursday expressed its support behind the Diabetic Testing Supply Access Act (S. 1935).
The legislation would allow independent community pharmacies to provide same-day delivery of diabetes testing supplies to Medicare beneficiaries and was introduced by Senss Jerry Moran, R-Kan., and John Thune, R-S.D.
Since July 1, 2013 community pharmacies have been banned from delivering DTS to beneficiaries, including those who are homebound or in long-term care or assisted living facilities.
“This winter has already brought sub-zero temperatures and perilous traveling and walking conditions to parts of the country,” stated NCPA CEO Douglas Hoey. “Pharmacists have reported cases of seniors going out in hazardous circumstances and risking a debilitating fall or other accident to obtain diabetes testing supplies because the local pharmacy can no longer deliver them. Now more than ever, Congress should scrap this indefensible delivery ban. We thank Sens. Moran and Thune for their leadership on this issue and for introducing this budget-neutral legislation.”
In July 2013, Rep. Peter Welch,D-Vt., introduced similar legislation in the House – The Diabetic Testing Supply Access Act (H.R. 2845).